139 related articles for article (PubMed ID: 20534237)
1. Induction with basiliximab plus thymoglobulin is effective and safe in old-for-old renal transplantation: six-month results of a prospective clinical study.
Favi E; Gargiulo A; Spagnoletti G; Salerno MP; Silvestrini N; Valente I; Citterio F
Transplant Proc; 2010 May; 42(4):1114-7. PubMed ID: 20534237
[TBL] [Abstract][Full Text] [Related]
2. Induction treatment with low-dose thymoglobulin or basiliximab in renal transplants from older donors.
Gavela Martínez E; Sancho Calabuig A; Escudero Quesada V; Avila Bernabeu AI; Beltrán Catalán S; Morales García AI; Crespo Albiach JF; Pallardó Mateu LM
Transplant Proc; 2008 Nov; 40(9):2900-2. PubMed ID: 19010141
[TBL] [Abstract][Full Text] [Related]
3. Induction Immunosuppressive Therapy Use in Deceased Donor Kidney Transplantation: 11-Year Experience in Veracruz, Mexico.
Martinez-Mier G; Soto-Miranda E; Avila-Pardo SF; Budar-Fernandez LF; Mateu-Rivera LJ; Mendez-Lopez MT; Trujillo-Martinez MF; Uscanga-Montesano A; Avila Y Falfan D
Transplant Proc; 2016 Mar; 48(2):600-4. PubMed ID: 27110011
[TBL] [Abstract][Full Text] [Related]
4. Histological findings of early graft biopsies in old donor renal transplant patients receiving induction therapy.
Gavela E; Pallardó LM; Sancho A; Avilla A; Beltrán S; Roselló E; Pérez ML; García F
Transplant Proc; 2009; 41(6):2099-101. PubMed ID: 19715842
[TBL] [Abstract][Full Text] [Related]
5. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression.
Gavela Martínez E; Avila Bernabeu AI; Sancho Calabuig A; Beltrán Catalán S; Escudero Quesada V; Pallardó Mateu LM
Transplant Proc; 2009; 41(6):2337-8. PubMed ID: 19715913
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
[TBL] [Abstract][Full Text] [Related]
7. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.
Knight RJ; Kerman RH; Schoenberg L; Podder H; Van Buren CT; Katz S; Kahan BD
Transplantation; 2004 Sep; 78(6):904-10. PubMed ID: 15385812
[TBL] [Abstract][Full Text] [Related]
8. Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial.
Martinez-Mier G; Moreno-Ley PI; Budar-Fernández LF; Méndez-López MT; Allende-Castellanos CA; Jiménez-López LA; Barrera-Amoros DA; Aguilar-Sandoval E; De la Paz-Román M; Soto-Miranda E; Rivera-Sanchez Y; Martínez-Maldonado M
Transplant Proc; 2021 Apr; 53(3):1005-1009. PubMed ID: 32178925
[TBL] [Abstract][Full Text] [Related]
9. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
10. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome.
Bazerbachi F; Selzner M; Boehnert MU; Marquez MA; Norgate A; McGilvray ID; Schiff J; Cattral MS
Transplantation; 2011 Nov; 92(9):1039-43. PubMed ID: 22002345
[TBL] [Abstract][Full Text] [Related]
11. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
[TBL] [Abstract][Full Text] [Related]
12. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
[TBL] [Abstract][Full Text] [Related]
13. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
14. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons.
Willoughby LM; Schnitzler MA; Brennan DC; Pinsky BW; Dzebisashvili N; Buchanan PM; Neri L; Rocca-Rey LA; Abbott KC; Lentine KL
Transplantation; 2009 May; 87(10):1520-9. PubMed ID: 19461489
[TBL] [Abstract][Full Text] [Related]
15. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
16. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
[TBL] [Abstract][Full Text] [Related]
17. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.
Lebranchu Y; Bridoux F; Büchler M; Le Meur Y; Etienne I; Toupance O; Hurault de Ligny B; Touchard G; Moulin B; Le Pogamp P; Reigneau O; Guignard M; Rifle G
Am J Transplant; 2002 Jan; 2(1):48-56. PubMed ID: 12095056
[TBL] [Abstract][Full Text] [Related]
18. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results.
Hardinger KL; Rhee S; Buchanan P; Koch M; Miller B; Enkvetchakul D; Schuessler R; Schnitzler MA; Brennan DC
Transplantation; 2008 Oct; 86(7):947-52. PubMed ID: 18852661
[TBL] [Abstract][Full Text] [Related]
19. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?
Jorge S; Guerra J; Silva S; Santana A; Mil-Homens C; Prata MM
Transplant Proc; 2008 Apr; 40(3):693-6. PubMed ID: 18454989
[TBL] [Abstract][Full Text] [Related]
20. Once daily everolimus is safe and effective in de novo renal transplant recipients: six-month results of a pilot study.
Favi E; Spagnoletti G; Gargiulo A; Salerno MP; Romagnoli J; Citterio F
Transplant Proc; 2010 May; 42(4):1308-11. PubMed ID: 20534287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
